INKT (MiNK Therapeutics, Inc. Common Stock) Stock Analysis - Analyst Ratings

MiNK Therapeutics, Inc. Common Stock (INKT) is a publicly traded Healthcare sector company. As of May 21, 2026, INKT trades at $10.29 with a market cap of $50.02M and a P/E ratio of -3.67. INKT moved +4.15% today. Year to date, INKT is -11.11%; over the trailing twelve months it is +48.60%. Its 52-week range spans $4.56 to $76.00. Analyst consensus is buy with an average price target of $35.00. Rallies surfaces INKT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What do analysts rate INKT?

1 analysts cover INKT: 0 strong buy, 1 buy, 0 hold, 0 sell, and 0 strong sell. The consensus rating is buy. The average price target is $35.00.

INKT Key Metrics

Key financial metrics for INKT
MetricValue
Price$10.29
Market Cap$50.02M
P/E Ratio-3.67
EPS$-2.93
Dividend Yield0.00%
52-Week High$76.00
52-Week Low$4.56
Volume9
Avg Volume0
Revenue (TTM)$180.25K
Net Income$-12.49M
Gross Margin0.00%

INKT Analyst Consensus

1 analysts cover INKT: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $35.00.

Latest INKT News

Recent INKT Insider Trades

  • Ryan Barbara sold 300 (~$4.58K) on Mar 10, 2026.
  • Ryan Barbara sold 500 (~$7.78K) on Mar 10, 2026.
  • Ryan Barbara sold 500 (~$7.65K) on Mar 10, 2026.

Common questions about INKT

What do analysts rate INKT?
1 analysts cover INKT: 0 strong buy, 1 buy, 0 hold, 0 sell, and 0 strong sell. The consensus rating is buy. The average price target is $35.00.
Does Rallies show INKT price targets?
Yes. Rallies tracks INKT analyst ratings, consensus rating, average price target, upgrades, downgrades, analyst firms, and recent price target changes when available.
Is INKT research on Rallies investment advice?
No. Rallies provides research, data, and educational context for INKT. It does not provide personalized investment advice.
INKT

INKT